STOCK TITAN

Insider sales and vesting disclosed at Vertex (NASDAQ: VRTX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Vertex Pharmaceuticals reported insider transactions and a restricted‑stock vesting event. The filing lists 1,182 common shares under "Securities To Be Sold" tied to Restricted Stock Vesting on 02/17/2026 as "Issuer" compensation. The filing also records sales by Mark E. Bunnage: 23 shares on 12/29/2025 (10,649.00), 2,021 shares on 02/11/2026 (930,529.03), and 2,437 shares on 02/17/2026 (1,192,814.02).

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

VRTX Latest News

VRTX Latest SEC Filings

VRTX Stock Data

121.26B
253.12M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON